Drug Profile
Research programme: monoclonal antibody biosimilars - XBiotech
Alternative Names: Cancer monoclonal antibody biosimilar - XBiotech; Inflammation monoclonal antibody biosimilar - XBiotechLatest Information Update: 27 Apr 2017
Price :
$50
*
At a glance
- Originator XBiotech
- Class Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer; Inflammation
Most Recent Events
- 16 Mar 2017 XBiotech has patent allowance for the administration of anti-interleukin-1 alpha antibodies to treat inflammatory skin diseases and psychiatric disorders in Australia
- 16 Mar 2017 XBiotech has patent protection for the administration of anti-interleukin-1 alpha antibodies for the treatment of cancer in Australia, New Zealand, Philippines, Singapore, and South Africa
- 16 Mar 2017 XBiotech has patent protection for the development of interleukin-1 alpha specific monoclonal antibodies in Australia, Chile, China, Europe, Hong Kong, Indonesia, Israel, Japan, South Korea, Malaysia, Mexico, New Zealand, Philippines, Russia, Singapore, South Africa and USA